Key Highlights

  • Viridian Therapeutics (NASDAQ:VRDN) was quoted at USD 28.66 in a published market data snapshot dated November 5, 2026, after gains of 50.84% over one month, 17.7% over one week, 24.72% over three months and 68.59% over six months.
  • Shares eased 1.36% in the latest session, and the company sits in the USD 2 billion to USD 10 billion Mid cap bracket, where it counts among the stronger biotech performers this month.
  • Quarterly filing figures show total Revenue of USD 25.8 million, with USD 24.7 million coming from net product sales of Lumvoa (veligrotug-vvze), against a net loss of USD 101.2 million, or USD 0.81 a share.
  • Cash and marketable securities stood at USD 955.2 million on September 30, 2026, a balance management believes can sustain planned operations for a minimum of 12 months, while 113,558,449 shares were outstanding on November 2, 2026.

First Lumvoa Revenue Appears in the Quarterly Filing

For the period ending September 30, 2026, Viridian Therapeutics (NASDAQ:VRDN) reported its first sales after the June 2026 FDA clearance of veligrotug, sold under the Lumvoa name for thyroid eye disease. Net product revenue was USD 24.7 million, license revenue USD 0.1 million and collaboration revenue USD 1.0 million, for total revenue of USD 25.8 million. Research and Development expense was USD 70.1 million in the quarter and USD 219.3 million over nine months, while selling, general and administrative expense was USD 57.6 million and USD 151.3 million. The quarterly net loss was USD 101.2 million, and the nine month loss reached USD 333.2 million, or USD 2.75 per share. A published coverage item cited a quarterly loss of 34 cents per share, a figure that is unconfirmed here.

Launch Ramp and Pipeline Steps Shape the Re-Rating Debate

Biotech shares often re-rate when first sales arrive, because investors can compare the revenue run rate with the cost base. Here the quarterly loss of USD 101.2 million is roughly four times net revenue, on simple arithmetic from two published numbers, so the debate centers on how fast Lumvoa scales. Other items include the pending EMA review of the veligrotug application filed in January 2026, a planned elegrobart BLA in the first quarter of 2027, FcRn inhibitor plans due in the fourth quarter of 2026, and a planned Phase 1 start for VRDN-292 in Graves' disease. No single catalyst for the past week was identified, so this is general context.

Cash Runway, Dilution Risk and Launch Execution Questions

The stock has gained 68.59% over six months and 50.84% over one month, so expectations are elevated. Cash of USD 172.9 million plus marketable securities of USD 782.3 million totals USD 955.2 million, and the company says that funds at least 12 months. Still, nine month operating spending of USD 370.6 million, calculated from research and development plus selling, general and administrative costs, implies continuing burn and possible future Equity raises that could dilute the 113.6 million shares outstanding. Launch metrics can disappoint, state distribution licenses are still pending, and a temporary title model is in use. Trading in a mid cap biotech can be volatile, and a small number of trades can move the price.

Where Things Stand

Viridian Therapeutics (NASDAQ:VRDN) gained 50.84% in a month because investors are rewarding first Lumvoa sales of USD 24.7 million and a cash position of USD 955.2 million, with regulatory and clinical steps still ahead. It ranks among the stronger mid cap gainers of the month in the snapshot, although the 1.36% dip in the latest session may reflect some profit taking. The quarterly loss of USD 101.2 million keeps cash burn central to the story. This is context, not advice.